Blog - Page 4068 of 5386

MondayNov 03, 2008 5:00 am

Prospect Acquisition Corporation (AMEX: PAX)

Prospect Acquisition Corporation (AMEX: PAX) is a newly organized blank check company formed for the purpose of acquiring control of, through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, one or more businesses or assets in the financial service industry. On November 20, 2007 Prospect completed an initial public offering of 25,000,000 units at an offering price of $10.00 per unit, generating gross proceeds of $250,000,000. For further information, visit the company website at: www.prospectac.com.

MondayNov 03, 2008 5:00 am

Cell Genesys, Inc. (NASDAQ: CEGE)

Cell Genesys, Inc. (NASDAQ: CEGE) has their focus on developing and commercializing novel biological therapies for cancer patients. GVAX® cancer imunotherapy, the company's lead product platform, holds the potential to treat several types of cancer. Cell Genesys also holds an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. For further information, visit the Company's web site at www.cellgenesys.com.

MondayNov 03, 2008 4:58 am

Celgene Corporation (NASDAQ: CELG)

Celgene Corporation (NASDAQ: CELG), a multinational biopharmaceutical company, is dedicated improving the lives of patients worldwide by delivering novel and life-changing drugs. Their aim is to build a major global biopharmaceutical corporation while discovering, developing, and commercializing products for the treatment of cancer and other severe, immune, inflammatory conditions. For further information, visit the Company's web site at www.celgene.com.

MondayNov 03, 2008 4:58 am

Pro-Pharmaceuticals, Inc. (AMEX: PRW)

Pro-Pharmaceuticals, Inc. (AMEX: PRW), a development-stage company, is focused on the discovery, development, and commercialization of first-in-class, targeted therapeutic compounds designed to treat cancer, liver, microbial and inflammatory diseases. The company’s current focus is on developing a new generation of anti-cancer treatments by utilizing carbohydrate polymers to improve survival rates and improve the quality of life for cancer patients. For further information, visit the Company's web site at www.pro-pharmaceuticals.com.

MondayNov 03, 2008 4:57 am

Prana Biotechnology Ltd. (NASDAQ: PRAN)

Prana Biotechnology Ltd. (NASDAQ: PRAN) has developed a proprietary portfolio of class-leading chemical compounds. The company combines this portfolio of compounds with a drug development program to discover novel therapeutics in multiple disease indications. Prana’s focus is currently on meeting the needs of patients diagnosed with neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases. For further information, visit the Company's web site at www.pranabio.com.

MondayNov 03, 2008 4:57 am

Cavico Corp. (OTC BB: CVIC)

Cavico Corp. (OTC BB: CVIC), a major infrastructure construction, infrastructure investment and natural resources conglomerate headquartered in Hanoi, Vietnam, is focused on large infrastructure projects, which include the construction of hydropower facilities, dams, bridges, tunnels, roads, mines and urban buildings. Cavico’s project partners include top multi-national corporations and government organizations. For further information, visit the Company's web site at www.cavicocorp.com.

MondayNov 03, 2008 4:57 am

Poniard Pharmaceuticals, Inc. (NASDAQ: PARD)

Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company, has their focus on developing and commercializing novel oncology products designed to impact the lives of people with cancer. Currently, the company’s development efforts are focused on picoplatin, a new generation of platinum chemotherapy agent that could potentially become a platform product. Poniard is studying this potential platform product in a number of cancer indications, combinations and formulations. For further information, visit the Company's web site at www.poniard.com.

MondayNov 03, 2008 4:57 am

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX), a specialty pharmaceutical company, is focused on developing and commercializing prescription drugs designed to treat drug addiction. Currently, CPP-109 is being developed to treat addiction to cocaine, methamphetamine and other addictive substances. The company’s mission is much larger than only serving their patients, as they also seek to benefit investors and the society at large. For further information, visit the Company's web site at www.catalystpharma.com.

MondayNov 03, 2008 4:56 am

Polaris Minerals Corporation (TSX: PLS CN)

Polaris Minerals Corporation (TSX: PLS CN) is solely focused on supplying construction aggregates to coastal urban markets on the western seaboard of North America. The company has targeted markets where accelerating local supply deficits and increasing road distribution costs allow marine transported aggregates to be competitive in the hub of key coastal urban markets. Polaris is led by CEO Marco Romero who has more than 28 years of experience in the mining industry. For further information, visit the Company's web site at www.polarmin.com.

MondayNov 03, 2008 4:56 am

Pluristem Therapeutics, Inc. (NASDAQ: PSTI)

Pluristem Therapeutics, Inc. (NASDAQ: PSTI), a bio-therapeutics company, has their focus on commercializing allogeneic (non-personalized) cell therapy products designed to treat a range of severe degenerative, ischemic and autoimmune disorders. Each of Pluristem’s products begin as mesenchymal stromal cells (MSCs). These cells are derived from the human placenta, an organ that has been considered medical waste after childbirth, but recognized by the company as a source of embryonic, non-controversial source of cells. For further information, visit the Company's web site at www.pluristem.com.

Site Search

Company Search

Prospect Acquisition Corporation (AMEX: PAX)

Cell Genesys, Inc. (NASDAQ: CEGE)

Celgene Corporation (NASDAQ: CELG)

Pro-Pharmaceuticals, Inc. (AMEX: PRW)

Prana Biotechnology Ltd. (NASDAQ: PRAN)

Cavico Corp. (OTC BB: CVIC)

Poniard Pharmaceuticals, Inc. (NASDAQ: PARD)

Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)

Polaris Minerals Corporation (TSX: PLS CN)

Pluristem Therapeutics, Inc. (NASDAQ: PSTI)

Market Basics

Newsletter Publishers

Public Companies